PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 78 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2014. The put-call ratio across all filers is 0.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $152,000 | -79.7% | 22,433 | -71.7% | 0.00% | -81.0% |
Q1 2017 | $749,000 | +77.5% | 79,369 | +62.5% | 0.02% | +110.0% |
Q4 2016 | $422,000 | +85.9% | 48,836 | +36.2% | 0.01% | +100.0% |
Q3 2016 | $227,000 | +23.4% | 35,845 | -18.0% | 0.01% | +25.0% |
Q2 2016 | $184,000 | +65.8% | 43,712 | +71.0% | 0.00% | +33.3% |
Q1 2016 | $111,000 | -28.4% | 25,570 | +1.2% | 0.00% | 0.0% |
Q4 2015 | $155,000 | -20.5% | 25,277 | -25.7% | 0.00% | 0.0% |
Q3 2015 | $195,000 | -44.1% | 34,027 | -27.2% | 0.00% | -50.0% |
Q2 2015 | $349,000 | +301.1% | 46,752 | +222.8% | 0.01% | +200.0% |
Q1 2015 | $87,000 | -56.3% | 14,482 | -44.9% | 0.00% | -33.3% |
Q4 2014 | $199,000 | +176.4% | 26,292 | +88.4% | 0.00% | +200.0% |
Q3 2014 | $72,000 | +41.2% | 13,958 | +11.0% | 0.00% | 0.0% |
Q1 2014 | $51,000 | -50.0% | 12,578 | -37.9% | 0.00% | 0.0% |
Q3 2013 | $102,000 | – | 20,267 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 17,902,338 | $135,342,000 | 5.88% |
TIGER MANAGEMENT L.L.C. | 1,288,454 | $9,741,000 | 1.91% |
Phocas Financial Corp. | 1,047,181 | $7,917,000 | 0.69% |
TUDOR INVESTMENT CORP ET AL | 2,370,503 | $17,921,000 | 0.62% |
EAM Investors, LLC | 553,309 | $4,183,000 | 0.58% |
Baker Brothers Advisors | 4,449,797 | $33,640,000 | 0.34% |
TFS CAPITAL LLC | 463,740 | $3,506,000 | 0.33% |
FEDERATED HERMES, INC. | 13,508,290 | $102,123,000 | 0.32% |
Rotella Capital Management, Inc. | 36,473 | $276,000 | 0.24% |
OXFORD ASSET MANAGEMENT LLP | 1,103,848 | $8,351,000 | 0.18% |